These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 10606278)

  • 1. Complications of advanced prostate cancer.
    Smith JA; Soloway MS; Young MJ
    Urology; 1999 Dec; 54(6A Suppl):8-14. PubMed ID: 10606278
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of pain and other symptoms of advanced prostatic cancer.
    Labasky RF; Smith JA
    Semin Urol; 1988 Nov; 6(4):311-21. PubMed ID: 3068769
    [No Abstract]   [Full Text] [Related]  

  • 3. Manifestations of advanced prostate cancer: prognosis and treatment.
    Surya BV; Provet JA
    J Urol; 1989 Oct; 142(4):921-8. PubMed ID: 2677414
    [No Abstract]   [Full Text] [Related]  

  • 4. Quality of life of patients with advanced and metastatic prostatic carcinoma.
    Villavicencio H
    Eur Urol; 1993; 24 Suppl 2():118-21. PubMed ID: 8262116
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Strontium-89 (Metastron) and the bisphosphonate olpadronate reduce the incidence of spinal cord compression in patients with hormone-refractory prostate cancer metastatic to the skeleton.
    Soerdjbalie-Maikoe V; Pelger RC; Lycklama à Nijeholt GA; Arndt JW; Zwinderman AH; Papapoulos SE; Hamdy NA
    Eur J Nucl Med Mol Imaging; 2002 Apr; 29(4):494-8. PubMed ID: 11914887
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The management of hormone-relapsed prostate cancer.
    Clarke NW
    BJU Int; 2003 Nov; 92(8):860-8. PubMed ID: 14616436
    [No Abstract]   [Full Text] [Related]  

  • 7. Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial.
    Logothetis CJ; Basch E; Molina A; Fizazi K; North SA; Chi KN; Jones RJ; Goodman OB; Mainwaring PN; Sternberg CN; Efstathiou E; Gagnon DD; Rothman M; Hao Y; Liu CS; Kheoh TS; Haqq CM; Scher HI; de Bono JS
    Lancet Oncol; 2012 Dec; 13(12):1210-7. PubMed ID: 23142059
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medical and surgical palliative care of patients with urological malignancies.
    Ok JH; Meyers FJ; Evans CP
    J Urol; 2005 Oct; 174(4 Pt 1):1177-82. PubMed ID: 16145365
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of the spectrum of hormone refractory prostate cancer.
    Clarke NW
    Eur Urol; 2006 Sep; 50(3):428-38; discussion 438-9. PubMed ID: 16797118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Treatment of bladder outlet obstruction in locally advanced prostate cancer].
    Martin L; Thiery-Vuillemin A; Kleinclauss F
    Prog Urol; 2013 May; 23(6):386-8. PubMed ID: 23628095
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Palliative care in urology.
    Wu JN; Meyers FJ; Evans CP
    Surg Clin North Am; 2011 Apr; 91(2):429-44, x. PubMed ID: 21419262
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Payer costs for inpatient treatment of pathologic fracture, surgery to bone, and spinal cord compression among patients with multiple myeloma or bone metastasis secondary to prostate or breast cancer.
    Barlev A; Song X; Ivanov B; Setty V; Chung K
    J Manag Care Pharm; 2010; 16(9):693-702. PubMed ID: 21067255
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Palliative and supportive treatment options in patients with advanced prostate cancer].
    Maurer T; Retz M; Gschwend JE
    Urologe A; 2007 Jan; 46(1):30-5. PubMed ID: 17211644
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Obstructive uropathy from locally advanced and metastatic prostate cancer: an old problem with new therapies.
    Friedlander JI; Duty BD; Okeke Z; Smith AD
    J Endourol; 2012 Feb; 26(2):102-9. PubMed ID: 22192109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Re: Palliative transurethral prostate resection for bladder outlet obstruction in patients with locally advanced prostate cancer.
    Engelhardt PF; Riedl CR
    J Urol; 2005 Jan; 173(1):324-5. PubMed ID: 15592105
    [No Abstract]   [Full Text] [Related]  

  • 16. Prevalence of skeletal complications and their impact on survival of hormone refractory prostate cancer patients in Japan.
    Inoue T; Segawa T; Kamba T; Yoshimura K; Nakamura E; Nishiyama H; Ito N; Kamoto T; Habuchi T; Ogawa O
    Urology; 2009 May; 73(5):1104-9. PubMed ID: 19394511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Bone metastases in lung cancer].
    Tsuya A; Fukuoka M
    Clin Calcium; 2008 Apr; 18(4):455-9. PubMed ID: 18379026
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The economic burden associated with skeletal-related events in patients with bone metastases secondary to solid tumors in Belgium.
    Body JJ; Chevalier P; Gunther O; Hechmati G; Lamotte M
    J Med Econ; 2013; 16(4):539-46. PubMed ID: 23425250
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Post-laminectomy long-term survival of a patient with spinal cord compression secondary to metastatic prostate cancer.
    Saito S; Hoshi S; Sakai K; Chiba Y; Saito H; Hatori M; Endoh M; Arai Y
    Int J Clin Oncol; 2004 Dec; 9(6):520-2. PubMed ID: 15616885
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical features of metastatic bone disease and risk of skeletal morbidity.
    Coleman RE
    Clin Cancer Res; 2006 Oct; 12(20 Pt 2):6243s-6249s. PubMed ID: 17062708
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.